According to filings with the U.S. Securities and Exchange Commission, Amprion is raising up to $15 Million in new funding. Sources indicate that as part of senior management Chief Executive Officer, Russell Lebovitz played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Amprion
Amprion pioneers Prion Early Detection Testing for Alzheimers and Parkinsons. For the first time in history, our proprietary molecular-based diagnostic technology tracks the biomarkers, aka prions including Abeta, Tau and Synuclein, that drive Alzheimers and Parkinsons prior to any clinical symptoms. Currently awarded FDA Breakthrough Device Designation for the detection of misfolded Synuclein, a biomarker for Parkinsons, the company is also applying the same assay to detect misfolded Abeta and Tau, which are known to cause Alzheimers. Amprion expects to obtain FDA approvals in the next 18 months and to launch various early detection testing for Alzheimers and Parkinsons accordingly. Early diagnosis of Alzheimers and Parkinsons empowers us to find a cure to stop these diseases on their tracks.

To learn more about Amprion, visit http://ampriondx.com/
Amprion Linkedin Page: https://www.linkedin.com/company/amprion/

Contact:
Russell Lebovitz, Chief Executive Officer
281-802-4776
https://www.linkedin.com/in/russlebovitz/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.